Ho J, Jou E, Khong P, Foo R, Sia C
Int J Mol Sci. 2024; 25(22).
PMID: 39596076
PMC: 11593553.
DOI: 10.3390/ijms252212010.
Sunagawa Y, Tsukabe R, Irokawa Y, Funamoto M, Suzuki Y, Yamada M
Int J Mol Sci. 2024; 25(4).
PMID: 38397020
PMC: 10889817.
DOI: 10.3390/ijms25042344.
Gladwell L, Ahiarah C, Rasheed S, Rahman S, Choudhury M
Life (Basel). 2024; 14(1).
PMID: 38255639
PMC: 10820772.
DOI: 10.3390/life14010023.
Chu L, Xie D, Xu D
Biomolecules. 2023; 13(9).
PMID: 37759781
PMC: 10526373.
DOI: 10.3390/biom13091382.
Kawase Y, Sunagawa Y, Shimizu K, Funamoto M, Hamabe-Horiike T, Katanasaka Y
Nutrients. 2023; 15(9).
PMID: 37432400
PMC: 10181444.
DOI: 10.3390/nu15092232.
Impact of polyphenols on heart failure and cardiac hypertrophy: clinical effects and molecular mechanisms.
Hedayati N, Yaghoobi A, Salami M, Gholinezhad Y, Aghadavood F, Eshraghi R
Front Cardiovasc Med. 2023; 10:1174816.
PMID: 37293283
PMC: 10244790.
DOI: 10.3389/fcvm.2023.1174816.
Roles of histone acetylation sites in cardiac hypertrophy and heart failure.
Funamoto M, Imanishi M, Tsuchiya K, Ikeda Y
Front Cardiovasc Med. 2023; 10:1133611.
PMID: 37008337
PMC: 10050342.
DOI: 10.3389/fcvm.2023.1133611.
Identification and Characterization of p300-Mediated Lysine Residues in Cardiac SERCA2a.
Gorski P, Lee A, Lee P, Oh J, Vangheluwe P, Ishikawa K
Int J Mol Sci. 2023; 24(4).
PMID: 36834924
PMC: 9959367.
DOI: 10.3390/ijms24043502.
Pharmacological inhibition of the acetyltransferase Tip60 mitigates myocardial infarction injury.
Wang X, Wan T, Kulik K, Lauth A, Smith B, Lough J
Dis Model Mech. 2022; 16(5).
PMID: 36341679
PMC: 9672930.
DOI: 10.1242/dmm.049786.
MicroRNA profiling of paediatric AML with or -rearrangements: Expression signatures and modulation of miR-221-3p and miR-222-3p with BRD4/HATs inhibitors.
Leoncini P, Vitullo P, Reddel S, Tocco V, Paganelli V, Stocchi F
Oncol Rep. 2022; 48(6).
PMID: 36321792
PMC: 9647495.
DOI: 10.3892/or.2022.8436.
Cardiac fibrosis in oncologic therapies.
Packard R
Curr Opin Physiol. 2022; 29.
PMID: 36187050
PMC: 9518957.
DOI: 10.1016/j.cophys.2022.100575.
Effects of high-absorption curcumin for the prevention of hypertensive heart disease: a double-blind, placebo-controlled, randomized clinical study.
Funamoto M, Sunagawa Y, Katanasaka Y, Kato T, Funada J, Ajiro Y
Eur Heart J Open. 2022; 2(5):oeac057.
PMID: 36172003
PMC: 9512148.
DOI: 10.1093/ehjopen/oeac057.
Study protocol to determine the effects of highly absorbable oral curcumin on the indicators of cognitive functioning: a double-blind randomised controlled trial.
Komiyama M, Ozaki Y, Wada H, Yamakage H, Satoh-Asahara N, Kishimoto A
BMJ Open. 2022; 12(9):e057936.
PMID: 36123102
PMC: 9486233.
DOI: 10.1136/bmjopen-2021-057936.
The roles and mechanisms of epigenetic regulation in pathological myocardial remodeling.
Zhao K, Mao Y, Li Y, Yang C, Wang K, Zhang J
Front Cardiovasc Med. 2022; 9:952949.
PMID: 36093141
PMC: 9458904.
DOI: 10.3389/fcvm.2022.952949.
Emerging epigenetic therapies of cardiac fibrosis and remodelling in heart failure: from basic mechanisms to early clinical development.
McKinsey T, Foo R, Anene-Nzelu C, Travers J, Vagnozzi R, Weber N
Cardiovasc Res. 2022; 118(18):3482-3498.
PMID: 36004821
PMC: 10202443.
DOI: 10.1093/cvr/cvac142.
Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors.
Han Y, Nie J, Wang D, Ni L
Front Cardiovasc Med. 2022; 9:931475.
PMID: 35958418
PMC: 9360326.
DOI: 10.3389/fcvm.2022.931475.
Pyrazole-Curcumin Suppresses Cardiomyocyte Hypertrophy by Disrupting the CDK9/CyclinT1 Complex.
Funamoto M, Sunagawa Y, Gempei M, Shimizu K, Katanasaka Y, Shimizu S
Pharmaceutics. 2022; 14(6).
PMID: 35745840
PMC: 9227296.
DOI: 10.3390/pharmaceutics14061269.
Epigenetic Modifications and Non-Coding RNA in Diabetes-Mellitus-Induced Coronary Artery Disease: Pathophysiological Link and New Therapeutic Frontiers.
Prandi F, Lecis D, Illuminato F, Milite M, Celotto R, Lerakis S
Int J Mol Sci. 2022; 23(9).
PMID: 35562979
PMC: 9105558.
DOI: 10.3390/ijms23094589.
Benefits of Curcumin in the Vasculature: A Therapeutic Candidate for Vascular Remodeling in Arterial Hypertension and Pulmonary Arterial Hypertension?.
Li K, Wang Z, Ongachwa Machuki J, Li M, Wu Y, Niu M
Front Physiol. 2022; 13:848867.
PMID: 35530510
PMC: 9075737.
DOI: 10.3389/fphys.2022.848867.
Okamura Extract Suppresses Myocardial Infarction-Induced Left Ventricular Systolic Dysfunction by Inhibiting p300-HAT Activity.
Katagiri T, Sunagawa Y, Maekawa T, Funamoto M, Shimizu S, Shimizu K
Nutrients. 2022; 14(3).
PMID: 35276939
PMC: 8838613.
DOI: 10.3390/nu14030580.